Transforming the arc of care

Intensive Care Units (ICUs) are Expensive

ICU cost burden totals

$254B

(1% US GDP)

High-cost patients comprise

10%

of total patients

High-cost patients consume

50%

of total resources

Inflammation is the key driver of complications and excess costs

Aurenar is on path to achieve tremendous health and economic impact by addressing inflammation - the underlying cause of life-threatening and costly complications in the ICU.

Our Approach

WEARABLE

NEUROMODULATION

Our ear-worn device boosts the body’s natural control of inflammation by activating a nerve located in the ear with imperceptible and non-invasive stimulation.

Meet Our Team

Meet Our Scientific Advisory Board

  • Greg Zipfel, MD

    Washington University

  • Salah Keyrouz, MD

    Washington University

  • Sander Connolly, MD

    Columbia University

  • Claude Hemphill, MD

    University of California, San Francisco

  • Dennis Rivet, MD

    Virginia Commonwealth University

  • Craig Coopersmith, MD

    Emory University

  • Huimahn Alex Choi, MD

    McGovern Medical School, UTHealth

Our approach has been successfully demonstrated in multiple randomized controlled clinical pilot studies, showing:

  • improved patient outcomes,

  • reduced hospital length of stay, and

  • lower cost of care.

We are excited to share our published results soon - stay tuned!

Clinical Trials

Awards

  • American Academy of Neurological Surgeons Award

  • American Association of Neurological Surgeons Award

  • Society of NeuroInterventional Surgery Award

  • Neurocricical Care Society Award

Get in touch.